With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
|Videos|October 7, 2016
Scrutiny of High Drug Costs Require Specialty Pharmacy Strategy Shift
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Advertisement
Related to this article
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
2
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Pharmacists' Role as Ketone Monitoring Reaches Clinics
5